232 related articles for article (PubMed ID: 11471773)
1. Midazolam and cortisol metabolism before and after CYP3A induction in humans.
Eeckhoudt SL; Desager JP; Robert AR; Leclercq I; Verbeeck RK; Horsmans Y
Int J Clin Pharmacol Ther; 2001 Jul; 39(7):293-9. PubMed ID: 11471773
[TBL] [Abstract][Full Text] [Related]
2. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
3. Increase in urinary excretion of 6beta-hydroxycortisol in common marmosets as a marker of hepatic CYP3A induction.
Totsuka S; Watanabe T; Koyanagi F; Tanaka K; Yasuda M; Manabe S
Arch Toxicol; 1999; 73(4-5):203-7. PubMed ID: 10463384
[TBL] [Abstract][Full Text] [Related]
4. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.
Shin KH; Ahn LY; Choi MH; Moon JY; Lee J; Jang IJ; Yu KS; Cho JY
AAPS J; 2016 Sep; 18(5):1254-1261. PubMed ID: 27317471
[TBL] [Abstract][Full Text] [Related]
5. Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females.
Lee J; Kim AH; Yi S; Lee S; Yoon SH; Yu KS; Jang IJ; Cho JY
AAPS J; 2017 Jul; 19(4):1196-1204. PubMed ID: 28523515
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Ushiama H; Echizen H; Nachi S; Ohnishi A
Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
[TBL] [Abstract][Full Text] [Related]
7. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
8. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
[TBL] [Abstract][Full Text] [Related]
9. Gas chromatography-mass spectrometry measurement of 6beta-OH-cortisol/cortisol ratio in human urine: a specific marker of enzymatic induction.
Luceri F; Fattori S; Luceri C; Zorn M; Mannaioni P; Messeri G
Clin Chem Lab Med; 2001 Dec; 39(12):1234-9. PubMed ID: 11798083
[TBL] [Abstract][Full Text] [Related]
10. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
Chan SW; Xiao Y; Hu M; Yin OQ; Chu TT; Fok BS; Lee VH; Tomlinson B
J Clin Pharm Ther; 2016 Oct; 41(5):552-8. PubMed ID: 27511886
[TBL] [Abstract][Full Text] [Related]
11. Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.
Chen YC; Gotzkowsky SK; Nafziger AN; Kulawy RW; Rocci ML; Bertino JS; Kashuba AD
Br J Clin Pharmacol; 2006 Aug; 62(2):187-95. PubMed ID: 16842393
[TBL] [Abstract][Full Text] [Related]
12. Changes in urinary 6beta-hydroxycortisol/cortisol ratio after birth in human neonates.
Nakamura H; Hirai M; Ohmori S; Ohsone Y; Obonai T; Sugita K; Niimi H; Kitada M
Eur J Clin Pharmacol; 1998 Jan; 53(5):343-6. PubMed ID: 9516034
[TBL] [Abstract][Full Text] [Related]
13. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.
Kinirons MT; O'Shea D; Kim RB; Groopman JD; Thummel KE; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 1999 Sep; 66(3):224-31. PubMed ID: 10511057
[TBL] [Abstract][Full Text] [Related]
14. Effect of troglitazone on urinary excretion of 6beta-hydroxycortisol.
Koup JR; Anderson GD; Loi CM
J Clin Pharmacol; 1998 Sep; 38(9):815-8. PubMed ID: 9753209
[TBL] [Abstract][Full Text] [Related]
15. Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.
Lee J; Yoon SH; Yi S; Kim AH; Kim B; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2019 Aug; 34(4):247-252. PubMed ID: 31088714
[TBL] [Abstract][Full Text] [Related]
16. Circadian variation of the urinary 6beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity.
Ohno M; Yamaguchi I; Ito T; Saiki K; Yamamoto I; Azuma J
Eur J Clin Pharmacol; 2000; 55(11-12):861-5. PubMed ID: 10805065
[TBL] [Abstract][Full Text] [Related]
17. Comparison of urinary 6beta-hydroxycortisol/cortisol ratio between neonates and their mothers.
Nakamura H; Hasegawa A; Kimura M; Yamagata S; Nakasa H; Osada H; Sekiya S; Ohmori S; Kitada M
Br J Clin Pharmacol; 1999 Jan; 47(1):31-4. PubMed ID: 10073736
[TBL] [Abstract][Full Text] [Related]
18. Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.
Streetman DS; Kashuba AD; Bertino JS; Kulawy R; Rocci ML; Nafziger AN
Pharmacogenetics; 2001 Jun; 11(4):349-55. PubMed ID: 11434513
[TBL] [Abstract][Full Text] [Related]
19. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
[TBL] [Abstract][Full Text] [Related]
20. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
Berger B; Kaufmann P; Koch A; Dingemanse J
J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
